91015-20-2

Upstream product

• 1209485-62-0 (1R,2R)-2-(diethylamino)cyclohexanaminium trifluoromethanesulfonate 
• 71444-30-9 (2SR)-2-[(SR)-hydroxy-(4-nitrophenyl)methyl]cyclohexanone 
• 320778-87-8 (3aR,7aR)-2-methyl-3a,4,5,6,7,7a-hexahydro-1H-benz[d]imidazole 
• 71172-32-2 trans-1,2-dinitrocyclohexane 
• 109-89-7 diethylamine 
• 286-18-0 7-azabicyclo[4.1.0]heptane 
• 1197208-38-0 N-((1R,2R)-2-aminocyclohexyl)benzamide 
• 20439-47-8 (1R,2R)-1,2-diaminocyclohexane 
• 1379686-01-7 N-[(1R,2R)-2-(diethylamino)cyclohexyl]benzamide 
• 1418742-15-0 (1R,2R)-N,N-diethyl-N'-phthaloyl-1,2-diaminocyclohexane 
• 320778-89-0 N-((1R,2R)-2-aminocyclohexyl)acetamide 

Downstream Products

• 849024-95-9 1-{3,5-bis(trifluoromethyl)phenyl}-3-{(1R,2R)-2-(diethylamino)cyclohexyl}urea 
• 1379685-87-6 2-[(1R,2R)-2-(diethylamino)cyclohexylamino]-7-(trifluoromethyl)quinazolin-4(3H)-one 
• 1414942-48-5 N-((1R,2R)-2-diethylaminocyclohexyl)-2-hydroxybenzamide 
• 1414942-49-6 N-((1R,2R)-2-diethylaminocyclohexyl)-2-ethoxybenzamide 
• 1414942-50-9 3,5-di-tert-butyl-N-((1R,2R)-2-diethylaminocyclohexyl)-2-hydroxybenzamide 
• 1414942-51-0 (S)-N-((1R,2R)-2-diethylaminocyclohexyl)-4-methyl-2-(4-methylphenylsulfonamino)pentanamide 
• 1414942-52-1 N,N'-bis((R,R)-2-diethylaminocyclohexyl)oxalylamide 
• 118768-63-1 trans-2-(N-pyrrolidinyl)cyclohexylamine 
• 1209485-62-0 (1R,2R)-2-(diethylamino)cyclohexanaminium trifluoromethanesulfonate 

Relevant academic research and scientific papers

New bifunctional organocatalysts based on (R,R)-cyclohexane-1,2-diamine for the asymmetric addition of nucleophiles to aldehydes

The amide and sulfamide derivatives of (1R,2R)-N,N-diethylcyclohexane-1,2- diamine can serve as organocatalysts for addition of Me3SiCN and Et2Zn to aldehydes.

Design and development of bioinspired guanine-based organic catalyst for asymmetric catalysis

Design, preparation, and studies of a family of new organic catalysts are presented. The design of the catalysts is inspired by the ability of DNA nucleobases to develop precise and explicit hydrogen bonds. We have shown that this phenomenon can be used to create a useful organic catalyst that demonstrates a recognition pattern similar to those of common organic substrates. A selected bifunctional catalyst based on a guanine structure has been shown to catalyze the conjugate addition of 1,3-dicarbonyl compounds to various nitroalkenes, providing the products in good yields and enantioselectivities.

Asymmetrie retro- and transfer-aldol reactions catalyzed by a simple chiral primary amine

(Chemical Figure Presented) One stone four birds: A single chiral primary amine was found to catalyze unprecedented asymmetric retro-aldol and transfer-aldol reactions, leading to four different chiral aldol adducts from one common chiral source with up to 99:1 d.r. and 99% ee (see scheme).

A simple primary-tertiary diamine-Bronsted acid catalyst for asymmetric direct aldol reactions of linear aliphatic ketones

Compared with the well-explored enamine catalysis with secondary amines, the development of efficient enamine-based primary amine catalysts has remained as an elusive goal until recently. We present herein that a simple chiral primary-tertiary diamine 1d

Structural optimization of thiourea-based bifunctional organocatalysts for the highly enantioselective dynamic kinetic resolution of azlactones

This article describes the synthesis of a library of structurally diverse bifunctional organocatalysts bearing both a quasi-Lewis acidic (thio)urea moiety and a Bronsted basic tertiary amine group. Sequential modification of the modular catalyst structure and subsequent screening of the compounds in the alcoholytic dynamic kinetic resolution (DKR) of azlactones revealed valuable structure-activity relationships. In particular, a "hit-structure" was identified which provides e.g. N-benzoyl-tert-leucine allyl ester in an excellent enantiomeric excess of 95%. The Royal Society of Chemistry 2006.

Method of treating chloroquine-resistant malaria with aminoquinoline derivatives

Novel aminoquinoline derivatives of the general formula STR1 are described. Also described are methods for the treatment of malaria pathogens, particularly chloroquine-resistance malaria pathogens with compounds of formula I or the pharmaceutically acceptable salts and hydrolyzable esters thereof.